HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical
and epidemiologic evidence show the role of HSV in increasing HIV infectiousness. The
evidence suggests that HSV is an important co-factor in HIV transmission.
The trial's purpose is to assess the reduction in HIV systemic and mucosal replication
associated with valacyclovir for suppression of HSV-2 reactivation.
This randomized, double-blind, placebo controlled crossover trial of 20 HIV/HSV-2 co-infected
women assessed the effects of daily valacyclovir on HIV-1 levels in blood and body fluids.
Phase:
Phase 3
Details
Lead Sponsor:
University of Washington
Collaborators:
Asociación Civil Impacta Salud y Educación, Peru GlaxoSmithKline